Publications by authors named "J M Perez-Hurtado"
Successful allogeneic CD34 hematopoietic stem cell boost for prolonged cytopenias following CAR T-cell therapy in B-cell acute lymphoblastic leukemia. On behalf of the Spanish Group for Hematopoietic Transplantation and Cellular Therapy (GETH-TC).
Bone Marrow Transplant
November 2024
Corrigendum: Impact of disease burden and late loss of B cell aplasia on the risk of relapse after CD19 chimeric antigen receptor T Cell (Tisagenlecleucel) infusion in pediatric and young adult patients with relapse/refractory acute lymphoblastic leukemia: role of B-cell monitoring.
Front Immunol
February 2024
[This corrects the article DOI: 10.3389/fimmu.2023.
View Article and Find Full Text PDFImpact of disease burden and late loss of B cell aplasia on the risk of relapse after CD19 chimeric antigen receptor T Cell (Tisagenlecleucel) infusion in pediatric and young adult patients with relapse/refractory acute lymphoblastic leukemia: role of B-cell monitoring.
Front Immunol
February 2024
Article Synopsis
- Loss of B-cell aplasia (BCA) is linked to the effectiveness of CD19 CAR-T therapy for B-cell acute lymphoblastic leukemia, with most relapses occurring in the first months post-infusion, particularly in patients with high tumor burden (HTB).
- A study of 73 patients showed that those with HTB had significantly lower event-free survival (EFS) rates (19.3%) compared to those with low tumor burden (LTB) (67.2%), and relapses were more likely to be CD19-negative in the HTB group.
- The findings suggest that BCA loss is associated with a higher risk of CD19-positive relapses and that patients with HTB might benefit from additional
Children with acquired hypocellular bone marrow failure of unknown cause (AHBMF) are usually diagnosed either with severe aplastic anemia (SAA) or refractory cytopenia of childhood (RCC). Patients with AHBMF who lack a matched donor and who failed or relapsed after immunosuppressive therapy (IST) need alternative therapies. Haploidentical hematopoietic stem cell transplantation (haplo-HSCT) offers a curative treatment for these patients.
View Article and Find Full Text PDFIntroduction: Studies addressing the role of haploidentical as alternative to HLA-matched donors for stem cell transplantation (SCT) often include patients with diverse hematological malignancies in different remission statuses.
Methods: We compared outcomes of children with acute lymphoblastic leukemia (ALL) undergoing SCT in second complete remission (CR2) from haploidentical (n = 25) versus HLA-matched donor (n = 51).
Results: Patients were equally distributed across both groups according to age, immunophenotype, time to and site of relapse, relapse risk-group allocation, and minimal residual disease (MRD) before SCT.